TLX Telix Pharmaceuticals Limited
Price Chart
Executive Summary
Telix announced publication of exploratory Phase 3 ZIRCON data in European Urology showing TLX250-Px PET/CT is highly predictive of renal malignancy across all subtypes, not just ccRCC, with a 98% positive predictive value. While this expands the potential utility of the imaging agent, the analysis is exploratory and not part of the pending BLA for ccRCC.
Actionable Insight
Monitor for additional studies or regulatory updates that could expand TLX250-Px's label to non-clear cell RCC, which would increase the addressable market.
Key Facts
- TLX250-Px PET/CT showed 98% positive predictive value for renal malignancy across all subtypes in exploratory analysis of ZIRCON trial data.
- Results published in European Urology, a leading peer-reviewed journal.
- The data are exploratory and not part of the BLA submission for ccRCC.
Financial Impact
No immediate financial impact; potential label expansion supports long-term value.
Risk Factors
- TLX250-Px is not yet approved for any indication; BLA for ccRCC remains the near-term catalyst.
- Exploratory data may not replicate in prospective studies or regulatory submissions.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287198 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
7d ago
|
Press Release
| $9.16 $8.77 | ▼ −4.26% | ▼ −3.54% | $9.22 (+0.66%) |
|
Jun 1, 2026
8d ago
|
Press Release
| $9.16 $8.77 | ▼ −4.26% | ▼ −3.54% | $9.22 (+0.66%) |
|
May 18, 2026
22d ago
|
Press Release
| $10.17 $10.28 | ▲ +1.08% | ▲ +0.04% | $9.22 (−9.34%) |
|
May 15, 2026
25d ago
|
Press Release
| $10.56 $10.28 | ▼ −2.65% | ▼ −2.59% | $9.22 (−12.69%) |
|
May 4, 2026
5w ago
|
Press Release
| $11.04 $11.11 | ▲ +0.63% | ▼ −0.75% | $9.22 (−16.49%) |
|
Apr 29, 2026
5w ago
|
Press Release
| $11.00 $11.26 | ▲ +2.36% | ▲ +2.14% | $9.22 (−16.18%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $10.33 $10.19 | ▼ −1.36% | ▼ −0.96% | $9.22 (−10.75%) |
|
Apr 13, 2026
8w ago
|
Press Release
| $11.24 $10.70 | ▼ −4.80% | ▼ −6.01% | $9.22 (−17.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access